|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.
This activity lays the foundation for understanding the disease state, the various clinical aspects of the drug class, and the pipeline involving this class of specialty pharmacy medications.
The target audience for this activity is pharmacists. Upon completion of this activity, participants will be able to:
- Discuss the pathophysiology of hypercholesterolemia.
- Discuss current treatments of hypercholesterolemia.
- Describe the function of PCSK9 in the body and how inhibition can affect low-density lipoprotein cholesterol (LDL-C) levels in the blood.
- Outline the Food and Drug Administration (FDA) approved indications, dosing, administration and adverse effects of alirocumab and evolocumab.
- Summarize clinical studies involving alirocumab and evolocumab.
- List pipeline molecules influencing PCSK9.
Erin Hohman, PharmD., BCPS
Director of Clinical Pharmacy Services
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Dr. Hohman has no relevant commercial or financial relationships to disclose.
The opinions expressed in this activity should not be construed as those of the CE provider. The information and views are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs for unlabeled indications. Use of drugs outside of labeling should be considered experimental and participants are advised to consult prescribing information and professional literature.
Release Date: 12-19-2018
Expiration Date: 12-19-2021
This CE activity is jointly provided by ProCE, Inc. and NASP. ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-18-393-H04-P has been assigned to this knowledge-based home-study CE activity (initial release date 12-19-18). This activity is approved for 0.75 contact hour (0.075 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 70% or higher are required to receive CE credit. No partial credit will be given.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.
|Activity Number||Credit Amount||Accreditation Period|
|0221-9999-18-393-H04-P||0.75 Contact Hours||December 19, 2018 - December 19, 2021|